Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints...
September 14, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Bionomics has collaborated with MSD to identify novel α7 nAChR PAMs suitable for the treatment of cognitive disorders like Alzheimer’s DiseaseBased on the learnings from Bionomics’ candidate BNC375,...
August 23, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

The last patient last visit has been completed in the Phase 2b ATTUNE study of BNC210 for the treatment of PTSDTopline results from Phase 2b ATTUNE study of BNC210 in patients with PTSD are expected...
July 31, 2023 06:00 ET | Source: Bionomics Ltd

Quarterly Activities and Cashflow Report

ADELAIDE, Australia, and CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company...
July 25, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)

ADELAIDE, Australia and CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or the Company) a clinical-stage biotechnology company developing...
July 03, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics...
June 15, 2023 08:00 ET | Source: Bionomics Ltd

Bionomics to Present at Upcoming June Investor Conferences

ADELAIDE, Australia and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing...
May 30, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company...
April 28, 2023 06:00 ET | Source: Bionomics Ltd

Quarterly Activities and Cashflow Report

ADELAIDE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel,...
April 27, 2023 06:00 ET | Source: Bionomics Ltd

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

ADELAIDE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel allosteric ion...

Next Page keyboard_arrow_right